Platinum-based combination chemotherapy±consolidation versus weekly cisplatin during adjuvant concurrent chemoradiation after radical hysterectomy in early cervical cancer patients with pelvic lymph node metastasis

Lee, Y.; Bae, Duk-Soo; Choi, Chel Hun; Jo, Eun Ju; Kim, H.; Kim, T.; Kim, B.; Lee, J.; Park, J.; Kim, M.

doi:10.1016/j.ygyno.2013.04.171

Cited by 7 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies 14,15,22 have reported that the number of metastatic LNs is an independent predictive factor for overall survival. Okazawa et al 15 investigated the prognostic significance of multiple PLN metastases in cervical cancer patients who were treated with radical hysterectomy plus adjuvant chemoradiotherapy.…”

Section: Discussionmentioning

confidence: 93%

The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy

Wei

Zhang

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 93%

The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy

Wei

Zhang

et al. 2016

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Surgery and radiation are common treatment options for patients with the early stages of cervical cancer [ 2 ]. Chemotherapy is often recommended for cases with the risk of postoperative recurrence, whereas combined regimes with chemotherapy and radiation are employed for those with late-stage disease [ 3 , 4 ]. Growing evidence has demonstrated that metastatic cervical cancer decreases the efficacy of radiotherapy or chemotherapy, and metastasis is the leading cause of death in cervical cancer patients [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-128 Confers Anti-Endothelial Adhesion and Anti-Migration Properties to Counteract Highly Metastatic Cervical Cancer Cells’ Migration in a Parallel-Plate Flow Chamber

Chuang

Tsai

et al. 2020

IJMS

View full text Add to dashboard Cite

Despite the distant metastasis of cervical cancer cells being a prominent cause of mortality, neither the metastasis capacity nor the in vitro conditions mimicking adhesion of cervical cancer cells to endothelial cells have been fully elucidated. Circulating metastatic cancer cells undergo transendothelial migration and invade normal organs in distant metastasis; however, the putative molecular mechanism remains largely uncertain. In this study, we describe the use of an in vitro parallel-plate flow chamber to simulate the dynamic circulation stress on cervical cancer cells and elucidate their vascular adhesion and metastasis. We isolate the viable and shear stress-resistant (SSR) cervical cancer cells for mechanistic studies. Remarkably, the identified SSR-HeLa and SSR-CaSki exhibited high in vitro adhesive and metastatic activities. Hence, a consistently suppressed miR-128 level was revealed in SSR cell clones compared to those of parental wild-type (WT) cells. Overexpressed miR-128 attenuated SSR-HeLa cells’ adherence to human umbilical cord vein endothelial cells (HUVECs); in contrast, suppressed miR-128 efficiently augmented the static adhesion capacity in WT-HeLa and WT-CaSki cells. Hence, amplified miR-128 modestly abolished in vitro SSR-augmented HeLa and CaSki cell movement, whereas reduced miR-128 aggravated the migration speed in a time-lapse recording assay in WT groups. Consistently, the force expression of miR-128 alleviated the SSR-enhanced HeLa and CaSki cell mobility in a wound healing assay. Notably, miR-128 mediated SSR-enhanced HeLa and CaSki cells’ adhesion and metastasis through suppressed ITGA5, ITGB5, sLex, CEACAM-6, MMP9, and MMP23 transcript levels. Our data provide evidence suggesting that miR-128 is a promising microRNA that prevented endothelial cells’ adhesion and transendothelial migration to contribute to the SSR-enhanced adhesion and metastasis progression under a parallel-plate flow chamber system. This indicates that the nucleoid-based miR-128 strategy may be an attractive therapeutic strategy to eliminate tumor cells resistant to circulation shear flow, prevent vascular adhesion, and preclude subsequent transendothelial metastasis.

show abstract

“… 30 Another study also proved that consolidation chemotherapy after radical hysterectomy + adjuvant CCRT could improve DFS in early stage cervical cancer patients with LNM. 31 A population-based cohort study using the Surveillance, Epidemiology, and End Results Program (SEER) showed that CCRT could not improve OS compared with radiotherapy alone for women with stage T1-2 cervical cancer with pelvic LNM. They suggested that the presence of LNM represents systemic disease with microscopic tumor spread.…”

Section: Resultsmentioning

confidence: 99%

Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review

Qin

Pang

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Cervical cancer is the fourth most common malignant tumor globally in terms of morbidity and mortality. The presence of lymph node metastasis (LNM) is an independent prognostic factor for progression-free survival (PFS) and overall survival (OS) in cervical cancer patients. The International Federation of Gynecology and Obstetrics (FIGO) staging system was revised in 2018. An important revision designates patients with regional LNM as stage IIIC, pelvic LNM only as stage IIIC1, and para-aortic LNM as stage IIIC2. However, the current staging system is only based on the anatomical location of metastatic lymph nodes (LNs). It does not consider other LN status parameters, which may limit its prognostic significance to a certain extent and needs further exploration and confirmation in the future. The purpose of this review is to summarize the choice of treatment for stage IIIC cervical cancer and the effect of different LN status parameters on prognosis.

show abstract

Platinum-based combination chemotherapy±consolidation versus weekly cisplatin during adjuvant concurrent chemoradiation after radical hysterectomy in early cervical cancer patients with pelvic lymph node metastasis

Cited by 7 publications

References 0 publications

The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy

The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy

MicroRNA-128 Confers Anti-Endothelial Adhesion and Anti-Migration Properties to Counteract Highly Metastatic Cervical Cancer Cells’ Migration in a Parallel-Plate Flow Chamber

Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review

Contact Info

Product

Resources

About